LetterLetter
Higher-dose Anakinra Is Effective in a Case of Medically Refractory Macrophage Activation Syndrome
PHILIP J. KAHN and RANDY Q. CRON
The Journal of Rheumatology May 2013, 40 (5) 743-744; DOI: https://doi.org/10.3899/jrheum.121098
PHILIP J. KAHN
New York University School of Medicine, Pediatrics, New York, New York;
MDRANDY Q. CRON
MD, PhD
REFERENCES
- 1.↵
- Fisher CJ Jr.,
- Dhainaut JF,
- Opal SM,
- Pribble JP,
- Balk RA,
- Slotman GJ,
- et al.
- 2.↵
- Behrens EM,
- Beukelman T,
- Paessler M,
- Cron RQ
- 3.↵
- Sawhney S,
- Woo P,
- Murray KJ
- 4.↵
- 5.↵
- Pascual V,
- Allantaz F,
- Arce E,
- Punaro M,
- Banchereau J
- 6.↵
- 7.↵
- 8.↵
- Miettunen PM,
- Narendran A,
- Jayanthan A,
- Behrens EM,
- Cron RQ
- 9.↵
- 10.↵
- Record JL,
- Beukelman T,
- Cron RQ
- 11.↵
- Verbsky JW,
- White AJ
- 12.↵
- Neven B,
- Marvillet I,
- Terrada C,
- Ferster A,
- Boddaert N,
- Couloignier V,
- et al.
In this issue
The Journal of Rheumatology
Vol. 40, Issue 5
1 May 2013
Higher-dose Anakinra Is Effective in a Case of Medically Refractory Macrophage Activation Syndrome
PHILIP J. KAHN, RANDY Q. CRON
The Journal of Rheumatology May 2013, 40 (5) 743-744; DOI: 10.3899/jrheum.121098